Polaryx Therapeutics Inc.
Polaryx Therapeutics Inc. (PLYX): 4 pipeline candidates · ~5 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.7 months
D/E 0.41 · 0% dilution
Lead: Phase 3
4 candidates
N/A
2 buys · 0 sells (180d)
A transparent, data-derived signal for Polaryx Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$109.4M
Cash
$3.1M
Quarterly Burn
$2.1M
Runway
4.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$29.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,316,776 | $25.1M |
| geode capital management, llc | 170,673 | $1.3M |
| millennium management llc | 127,525 | $964K |
| vanguard fiduciary trust co | 104,556 | $790K |
| state street corp | 58,104 | $439K |
| blackrock, inc. | 41,012 | $310K |
| northern trust corp | 27,987 | $212K |
| bank of america corp /de/ | 25,881 | $196K |
| goldman sachs group inc | 13,483 | $102K |
| squarepoint ops llc | 12,406 | $94K |
Showing top 10 of 13 institutional holders of Polaryx Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Polaryx Therapeutics Inc.'s pipeline?
Polaryx Therapeutics Inc. (PLYX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Polaryx Therapeutics Inc.'s lead drug candidate?
Polaryx Therapeutics Inc.'s most advanced tracked candidate is plx-100 (Phase 3) for LSDs (specifically CLN2).
What is Polaryx Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Polaryx Therapeutics Inc. has approximately 4.7 months of cash runway.
What is Polaryx Therapeutics Inc.'s market capitalization?
Polaryx Therapeutics Inc.'s market capitalization is approximately $109.4M.
Who is the CEO of Polaryx Therapeutics Inc.?
Mr. Alex Yang J.D., L.L.M. is the chief executive officer of Polaryx Therapeutics Inc. (PLYX).
Get the full picture on Polaryx Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.